About Shattuck Labs Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.shattucklabs.com/
Frequently Asked Questions
What is the 52-week range for STTK?
The 52-week high is $8.33 and the 52-week low is $1.7.
What is the P/E ratio for STTK?
The P/E ratio data is currently unavailable.
What is the dividend yield for STTK?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -43.57%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1005.60%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.80.
Analyst Recommendation Trends
Wall Street analyst consensus for STTK over the last few months:
Latest STTK News
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14
Wedbush analyst David Nierengarten maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and raises the price target from $11 to $14.
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Needham analyst Joseph Stringer maintains Shattuck Labs (NASDAQ:STTK) with a Buy and raises the price target from $17 to $19.
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
– RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028 – – HS is the second Phase 2 indication for SL-325 and expands development beyond IBD – – Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program – – Cash runway guidance remains unchange
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-06 | Shukla Abhinav A. | -12,153 | - | - |
| 2026-07-06 | Shukla Abhinav A. | +12,153 | $3.57 | $43,386 |
| 2026-07-02 | Shukla Abhinav A. | -410 | - | - |
| 2026-07-02 | Shukla Abhinav A. | -410 | $7.01 | $2,874 |
| 2026-07-02 | Shukla Abhinav A. | +410 | $3.57 | $1,464 |
| 2026-07-01 | Shukla Abhinav A. | -100 | - | - |
| 2026-07-01 | Shukla Abhinav A. | -100 | $7.07 | $707 |
| 2026-07-01 | Shukla Abhinav A. | +100 | $3.57 | $357 |
| 2026-06-30 | Shukla Abhinav A. | -23,365 | - | - |
| 2026-06-30 | Shukla Abhinav A. | -23,365 | $7.08 | $165,424 |
| 2026-06-30 | Shukla Abhinav A. | +23,365 | $3.57 | $83,413 |
| 2026-06-30 | Pandite Arundathy N. | -30,000 | $7.01 | $210,300 |
| 2026-06-11 | Ashiya Mona | +208,333 | - | - |
| 2026-06-11 | Ashiya Mona | +1,041,667 | - | - |
| 2026-06-11 | ORBIMED ADVISORS LLC | +208,333 | - | - |
| 2026-06-11 | ORBIMED ADVISORS LLC | +1,041,667 | - | - |
| 2026-06-09 | SIEGALL CLAY B | +62,500 | $4 | $250,000 |
| 2026-06-08 | Ashiya Mona | -3,073,298 | - | - |
| 2026-06-08 | Ashiya Mona | -15,366,490 | - | - |
| 2026-06-08 | Ashiya Mona | +3,073,298 | - | - |
| 2026-06-08 | Ashiya Mona | +15,366,490 | - | - |
| 2026-06-08 | ORBIMED ADVISORS LLC | -3,073,298 | - | - |
| 2026-06-08 | ORBIMED ADVISORS LLC | -15,366,490 | - | - |
| 2026-06-08 | ORBIMED ADVISORS LLC | +3,073,298 | - | - |
| 2026-06-08 | ORBIMED ADVISORS LLC | +15,366,490 | - | - |
| 2026-05-29 | Baker Daniel G. | +81,000 | - | - |
| 2026-05-29 | Ashiya Mona | +81,000 | - | - |
| 2026-05-29 | Boudreau Helen M | +81,000 | - | - |
| 2026-05-29 | Golumbeski George | +81,000 | - | - |
| 2026-05-29 | Gibson Neil W | +81,000 | - | - |
| 2026-05-29 | SIEGALL CLAY B | +81,000 | - | - |
| 2026-05-22 | SIEGALL CLAY B | -128,054 | - | - |
| 2026-05-22 | SIEGALL CLAY B | +128,054 | $1.0846 | $138,887 |
| 2026-05-21 | Shukla Abhinav A. | -5,122 | - | - |
| 2026-05-21 | Shukla Abhinav A. | +5,122 | $1.0846 | $5,555 |
| 2026-05-15 | Stout Stephen | -12,805 | - | - |
| 2026-05-15 | Stout Stephen | +12,805 | $1.0846 | $13,888 |
| 2026-05-12 | Neill Andrew R | -64,027 | - | - |
| 2026-05-12 | Neill Andrew R | +64,027 | $1.0846 | $69,444 |
| 2026-05-12 | Shukla Abhinav A. | -2,032 | - | - |
| 2026-05-12 | Shukla Abhinav A. | -2,032 | $7.01 | $14,244 |
| 2026-05-12 | Shukla Abhinav A. | +2,032 | $3.57 | $7,254 |
| 2026-05-12 | Pandite Arundathy N. | -30,000 | $6.61 | $198,300 |
| 2026-05-12 | Schreiber Taylor | -25,610 | - | - |
| 2026-05-12 | Schreiber Taylor | +25,610 | $1.0846 | $27,777 |
| 2026-05-10 | Stout Stephen | -968 | $6.85 | $6,631 |
| 2026-01-25 | Pandite Arundathy N. | -3,195 | $4.15 | $13,259 |
| 2026-01-25 | Stout Stephen | -593 | $4.15 | $2,461 |
| 2026-01-25 | Neill Andrew R | -2,589 | $4.15 | $10,744 |
| 2026-01-25 | DeYoung Casi | -2,286 | $4.15 | $9,487 |
| 2026-01-10 | Stout Stephen | +351,400 | - | - |
| 2026-01-10 | Stout Stephen | -4,153 | $4.75 | $19,727 |
| 2026-01-10 | Shukla Abhinav A. | +315,500 | - | - |
| 2026-01-10 | Pandite Arundathy N. | +487,800 | - | - |
| 2026-01-10 | Pandite Arundathy N. | -6,851 | $4.75 | $32,542 |
| 2026-01-10 | Neill Andrew R | +549,800 | - | - |
| 2026-01-10 | Neill Andrew R | -6,660 | $4.75 | $31,635 |
| 2026-01-10 | DeYoung Casi | +381,600 | - | - |
| 2026-01-10 | DeYoung Casi | -5,699 | $4.75 | $27,070 |
| 2026-01-10 | Schreiber Taylor | +1,548,300 | - | - |